Drugs / RC28-E
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03777254 | Jan → Aug 2019 | wet macular degeneration | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04270669 | Apr 2020 → Oct 2021 | wet macular degeneration | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04782128 | May 2021 → May 2024 | diabetic retinopathy | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04782115 | Mar 2021 → Jul 2023 | diabetic macular edema | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05885503 | Jun 2023 → Jun 2026 | diabetic macular edema | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05727397 | Mar 2023 → Nov 2025 | wet macular degeneration | RemeGen Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC28-E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727397 ↗ |
| Action | Inhibit | “can block vascular endothelial growth factor (VEGFA), platelet-derived growth factor (PDGF), and fibroblast growth factor-2 (FGF-2) simultaneously” PMID 31652997 ↗ Oct 2019 |
| Modality | Protein / enzyme biologic | “RC28-E is a novel recombinant dual decoy receptor lgG1 Fc-fusion protein” PMID 31652997 ↗ Oct 2019 |
| Route | Intravitreal | “single intravitreal injections of RC28-E” NCT03777254 ↗ |
| Target | VEGFA | “block vascular endothelial growth factor (VEGFA)” PMID 31652997 ↗ Oct 2019 |